April 17, 2012 Lancet Oncology Study
Study shows significant side effect reduction with HIFU to treat prostate cancer... more >
Sky News, April 17, 2012 Prostate Cancer Treatment 'Reduces Side Effects'
A high-powered beam of ultrasound can destroy prostate cancer without causing the serious side effects... more >
Urology Times, May 1, 2012 Data show low morbidity of HIFU in short-term trials
Technique appears safe, but evaluation of efficacy awaits longer-term data... more >
High intensity focused ultrasound, or HIFU, is a minimally invasive therapy option for localised prostate cancer that may offer a balance between eliminating cancer and maintain quality of life. The Sonablate® 500 “Sonablate” uses precisely focused ultrasound waves that, when delivered, raise the temperature of the targeted prostate tissue to 80-90 degrees Celsius in 2-3 seconds. This rapid-firing heat destroys the targeted tissue while leaving healthy structures outside the prostate gland unharmed.
Euro HIFU is the division of UKHIFU Limited responsible for sales and technical operations in continental Europe and is
committed to a new standard for the treatment of prostate cancer
with the Sonablate HIFU medical device. This website explores
the Sonablate HIFU procedure for prostate cancer patients located
throughout Europe.
This
site complies to the